Skip to main content

Advertisement

SpringerLink
Log in

Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objectives

It has been shown that exposure to some environmental toxins may induce scleroderma-like illness in predisposed individuals, but the etiopathogenesis of the idiopathic form of systemic sclerosis (SSc) remains obscure. The genetic background of this illness has been confirmed in multiple studies. We investigated whether patients with SSc differ from healthy subjects with regard to the enzymatic activity of polymorphic N-acetyltransferase 2 (NAT2).

Methods

The study was carried out in 39 patients with SSc; 15 fulfilled the criteria of diffuse SSc (dSSc) and 24 of limited SSc (lSSc); an ethnically matched control group consisted of 100 healthy volunteers. Acetylation phenotype was estimated using the isoniazid as a model drug. The most common mutations in the Caucasian population at positions 481T, 803G, 590A and 857A on the NAT2 gene were determined using the polymerase chain reaction–restriction fragment length polymorphism method with deoxyribonucleic acid (DNA) extracted from peripheral blood.

Results

In the group of patients with SSc, the frequency of fast acetylator genotypes was 38.5% (95% CI 23.4–55.4), while that for the genotypes coding slow acetylator status was 51.3% (95% CI 34.8–67.6).There was a strong correlation between NAT2 phenotype and NAT2 genotype with a concordance of 97%. We did not observe a preponderance of slow acetylators among patients with SSc and in two subsets of SSc. With the sample size analyzed in the present study, there is a 90% probability of detecting significant differences in distribution of slow, fast, and intermediate phenotypes between patients with SSc and controls, there is a difference of at least 30.3, 28.7 and 21.9% in the distribution of these phenotypes in the general population, respectively.

Conclusion

Acetylator status does not seem to be the significant factor in the development of SSc in patients with both subsets of this autoimmune disease, but further studies are required to confirm this conclusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Haustein UF (2002) Systemic sclerosis—scleroderma. Dermatol Online J 8:3

    Google Scholar 

  2. Mayes MD (2000) Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect 107:743–748

    Google Scholar 

  3. Johnson RW, Tew MB, Arnett FC (2002) The genetics of systemic sclerosis. Curr Rheumatol Rep 4:99–107

    PubMed  Google Scholar 

  4. Vatsis KP, Weber WW, Bell DA (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1–7

    CAS  PubMed  Google Scholar 

  5. Hein DW, Doll MA, Fretland AJ, Leff AM, Webb SJ, Xiao GH et al (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphism. Cancer Epidemiol Biomarkers Prev 9:29–42

    CAS  PubMed  Google Scholar 

  6. Pompeo F, Brooke E, Kawamura A, Mushtag A, Sim E (2002) The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 3:19–30

    CAS  PubMed  Google Scholar 

  7. Fretland AJ, Leff AM, Doll MA, Hein DW (2001) Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphism. Pharmacogenetics 11:207–215

    Article  CAS  PubMed  Google Scholar 

  8. Cascorbi I, Brockmöller J, Mrozikiewicz A, Roots I (1999) Arylamine N-acetyltransferase activity in man. Drug Met Rev 31:489–502

    Article  CAS  Google Scholar 

  9. Masi AT, Rodnana GP, Medsger TAJ (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    PubMed  Google Scholar 

  10. Le Roy EC, Black C, Fleischmayer R (1998) Scleroderma (SSC): classification, subsets, and pathogenesis. J Rheumatol 15:202–204

    Google Scholar 

  11. Weller TH, Coons AH (1954) Fluorescent antibody studies with agents of varicella and herpes zoster propagated in vitro. Proc Soc Exp Biol Med 86:789

    CAS  PubMed  Google Scholar 

  12. Ouchterlony O (1962) Diffusion-in-gel methods for immunological analysis. In: Callos P, Waxman BH (eds) Progress in allergy, vol 5. Karger, New York, pp 30–40

  13. Eidus L,Varughese P, Hodgkin MM, Hsu AHE, McRae KB (1973) Simplification of isoniazid phenotyping procedure to promote its application in the chemotherapy of tuberculosis. Bull World Health Org 49:507–511

    CAS  PubMed  Google Scholar 

  14. Gustincich S, Manfioletti G, Del Sal G, Carninci P (1991) A fast method for high-quality genomic DNA extraction from whole blood. Biotechniques 11:298–302

    CAS  PubMed  Google Scholar 

  15. Spurr NK, Gough AC, Chinegwundoh FI, Smith CA (1995) Polymorphism in drug-metabolizing enzymes as modifiers of cancer risk. Clin Chem 41:1864–1869

    CAS  PubMed  Google Scholar 

  16. Pawlik A, Ostanek L, Brzosko I, Gawronska-Szklarz B, Brzosko M, Zamojcin-Dąbrowska E (2002) Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis. Clin Pharmacol Ther 72:319–325

    Article  CAS  PubMed  Google Scholar 

  17. Zschieschang P, Hiepe F, Gromnica-Ihle E, Roots I, Cascorbi I (2002) Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics 12:559–563

    Article  CAS  PubMed  Google Scholar 

  18. Larrson R, Karlsen E, Molin L (1977) Spontaneous systemic lupus erythematosus and acetylator phenotype. Acta Med Scand 201:226–232

    Google Scholar 

  19. Sonnhag C, Karlsson E, Hed J (1979) Procainamide induced lupus erythematosus like syndrome in relation to acetylator phenotype and plasma levels of procainamide. Acta Med Scand 206:245–251

    CAS  PubMed  Google Scholar 

  20. Strandberg I, Boman G, Hassler L, Sjoqvist F (1976) Acetylator phenotype in patients with hydralazine induced lupoid syndrome. Acta Med Scand 200:367–371

    CAS  PubMed  Google Scholar 

  21. Yung RL, Quddus J, Crisp CE, Johnson KJ, Richardson BC (1995) Mechanism of drug induced lupus. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025–3035

    CAS  PubMed  Google Scholar 

  22. Dubroff LM, Reid RL (1980) Hydralazine–pyrimidine interactions may explain hydralazine induced lupus erythematosus. Science 208:404–406

    CAS  PubMed  Google Scholar 

  23. Tomura T, van Lencer JL (1988) Procainamide–DNA interaction. J Rheumatol 15:59–64

    CAS  PubMed  Google Scholar 

  24. Jiang X, Khurisigara G, Rubin RL (1994) Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266:810–813

    CAS  PubMed  Google Scholar 

  25. Mongey AB, Sim E, Risch A, Hess E (1999) Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide. J Rheumatol 26:1721–1726

    CAS  PubMed  Google Scholar 

  26. Povey A, Guppy MJ, Wood M, Knight C, Black CM, Silman AJ (2001) Cytochrome P2 polymorphism and susceptibility to scleroderma following exposure to organic solvents. Arthritis Rheum 44:662–665

    CAS  PubMed  Google Scholar 

  27. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, Porter JA, Wilkinson GR, Branch RA (1990) Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquine, and mephenytoin. Clin Pharmacol Ther Sep 48:286–295

    CAS  Google Scholar 

  28. von Schmiedeberg S, Fritsche E, Ronnau AC, Specker C, Golka K, Richter-Hinz D et al (1999) Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 45:147–152

    Google Scholar 

  29. Palmer CNA, Young V, Ho M, Doney A, Belch JJ (2003) Association of common variation in glutathione S-transferase genes with premature development of cardiovascular disease in patients with systemic sclerosis. Arthritis Rheum 48:854–855

    Article  CAS  PubMed  Google Scholar 

  30. Tew MB, Reveille JD, Arnett FC et al (2001) Glutathione S-transferase genotypes in systemic sclerosis and their association with clinical manifestation in early disease. Genes Immun 2:236–238

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by grant no. 502-11-763 from the Medical University of Lodz, Poland.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Clinical Pharmacology , Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland

    K. Skrętkowicz, J. Skrętkowicz & M. Rychlik-Sych

  2. Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Academy of Medicine, Szczecin, Poland

    B. Gawrońska-Szklarz & W. Górnik

  3. Department of Dermatology and Venerology, Medical University of Lodz, Poland

    A. Sysa-Jędrzejowska

Authors
  1. K. Skrętkowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Skrętkowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Gawrońska-Szklarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Górnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Rychlik-Sych
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Sysa-Jędrzejowska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Skrętkowicz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skrętkowicz, K., Skrętkowicz, J., Gawrońska-Szklarz, B. et al. Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis. Eur J Clin Pharmacol 60, 773–778 (2005). https://doi.org/10.1007/s00228-004-0837-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0837-x

Keywords

Search

Navigation